PKA and CDK5 Can Phosphorylate Specific Serines on the Intracellular Domain of Podoplanin (PDPN) to Inhibit Cell Motility. by Krishnan, Harini et al.
Rowan University
Rowan Digital Works
School of Osteopathic Medicine Faculty
Scholarship School of Osteopathic Medicine
7-1-2015
PKA and CDK5 Can Phosphorylate Specific
Serines on the Intracellular Domain of Podoplanin
(PDPN) to Inhibit Cell Motility.
Harini Krishnan
Rowan University School of Osteopathic Medicine
Edward Retzbach







See next page for additional authors
Let us know how access to this document benefits you - share your
thoughts on our feedback form.
Follow this and additional works at: https://rdw.rowan.edu/som_facpub
Part of the Biochemistry Commons, Biology Commons, Cell Biology Commons, and the
Molecular Biology Commons
This Article is brought to you for free and open access by the School of Osteopathic Medicine at Rowan Digital Works. It has been accepted for
inclusion in School of Osteopathic Medicine Faculty Scholarship by an authorized administrator of Rowan Digital Works. For more information, please
contact jiras@rowan.edu, rdw@rowan.edu.
Recommended Citation
Krishnan, Harini; Retzbach, Edward; Ramirez, Maria; Liu, Tong; Li, Hong; Miller, W.; and Goldberg, Gary, "PKA and CDK5 Can
Phosphorylate Specific Serines on the Intracellular Domain of Podoplanin (PDPN) to Inhibit Cell Motility." (2015). School of
Osteopathic Medicine Faculty Scholarship. 76.
https://rdw.rowan.edu/som_facpub/76
Authors
Harini Krishnan, Edward Retzbach, Maria Ramirez, Tong Liu, Hong Li, W. Miller, and Gary Goldberg
This article is available at Rowan Digital Works: https://rdw.rowan.edu/som_facpub/76
PKA and CDK5 can phosphorylate specific serines on the 
intracellular domain of podoplanin (PDPN) to inhibit cell motility
Harini Krishnana, Edward P. Retzbacha, Maria I. Ramirezb, Tong Liuc, Hong Lic, W. Todd 
Millerd, and Gary S. Goldberga,e
aGraduate School of Biomedical Sciences and Department of Molecular Biology Science Center, 
2 Medical Center Dr. Rowan University School of Osteopathic Medicine, Stratford, NJ 08084, 
USA
bPulmonary Center, Department of Medicine, Boston University School of Medicine, Boston, MA 
02118, USA
cCenter for Advanced Proteomics Research and Department of Biochemistry and Molecular 
Biology, Rutgers New Jersey Medical School Cancer Center, 205 S. Orange Avenue, F-1226, 
Newark, NJ 07103, USA
dDepartment of Physiology and Biophysics, Basic Science Tower T-5, Stony Brook University, 
Stony Brook, NY, 11794-8661, USA
Abstract
Podoplanin (PDPN) is a transmembrane glycoprotein that promotes tumor cell migration, 
invasion, and cancer metastasis. In fact, PDPN expression is induced in many types of cancer. 
Thus, PDPN has emerged as a functionally relevant cancer biomarker and chemotherapeutic 
target. PDPN contains 2 intracellular serine residues that are conserved between species ranging 
from mouse to humans. Recent studies indicate that protein kinase A (PKA) can phosphorylate 
PDPN in order to inhibit cell migration. However, the number and identification of specific 
residues phosphorylated by PKA have not been defined. In addition, roles of other kinases that 
may phosphorylate PDPN to control cell migration have not been investigated. We report here that 
cyclin dependent kinase 5 (CDK5) can phosphorylate PDPN in addition to PKA. Moreover, 
results from this study indicate that PKA and CDK5 cooperate to phosphorylate PDPN on both 
intracellular serine residues to decrease cell motility. These results provide new insight into PDPN 
phosphorylation dynamics and the role of PDPN in cell motility. Understanding novel 
mechanisms of PDPN intracellular signaling could assist with designing novel targeted 
chemotherapeutic agents and procedures.
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Podoplanin (PDPN) is a unique transmembrane receptor glycoprotein. Tumor promoters 
including TPA [1], RAS [2], TGF-β1, IFN-γ [3], EGFR [4], and Src [5] induce PDPN 
expression. PDPN regulates the activities of Rho, ezrin, and other proteins linked to the actin 
cytoskeleton to mediate filopodia formation, cell motility, invasion, and metastasis [6, 7].
PDPN expression is critical for embryonic development, and is upregulated in many types of 
cancer [6, 8–10]. For example, PDPN promotes the motility and invasion of many 
transformed cell types including mammary carcinoma [6, 11], glioma [12], and oral 
squamous carcinoma cells [13–15]. PDPN is also expressed by lymphatic endothelial cells 
[16, 17] and cancer associated fibroblasts [18–20] which can augment tumor invasion and 
metastasis [19, 21, 22].
PDPN can serve as a functionally relevant tumor biomarker, and is an enticing 
chemotherapeutic target. Indeed, the extracellular domain of PDPN can be targeted by 
antibodies and specific lectins to suppress tumor cell growth and migration [15, 23–28]. 
However, signaling events mediated by the intracellular domain of PDPN may also 
illuminate mechanisms leading to cell motility and pathways to chemotherapy that have not 
been explored.
The PDPN intracellular domain consists of about 10 amino acids that direct interactions with 
ERM proteins to affect the actin cytoskeleton [29]. This domain contains 2 conserved serine 
residues that can be phosphorylated to decrease PDPN mediated cell migration [18]. 
However, specific kinases that phosphorylate these individual serine residues, and how these 
phosphorylation events affect cell migration, have not been clearly elucidated. Here, we 
present data indicating that PKA and CDK5 kinases cooperate to phosphorylate both serines 
in the intracellular tail of PDPN in order to decrease cell motility.
Materials and Methods
Immunoprecipitation and Western blot analysis
Cells were lysed in RIPA buffer (50mM Tris-HCl pH 7.4, 1% NP-40, 2.5mM sodium 
pyrophosphate, 150mM sodium chloride, 1mm EDTA, 1mM EGTA, 1mM sodium 
betaglycerophosphate, 1mM sodium orthovanadate, 50mM sodium fluoride, 1mM PMSF, 
10µg/mL protease inhibitor cocktail) and clarified by centrifugation at 20000 g for 5 
minutes. Lysates containing 5mg of protein were incubated with phosphoserine antibody 
16B4 (Enzo ALX-804-167-C100) [30, 31] for 3h at 4°C followed by protein-L beads (Santa 
Cruz 2336) for 1.5h at 4°C. Immune complexes were washed four times with ice-cold PBS 
supplemented with 1mM sodium orthovanadate, 50mM sodium fluoride, 1mM PMSF, and 
10µg/mL protease inhibitor cocktail, eluted in sample buffer, resolved on 12% SDS-PAGE 
gels, and transferred to Immobilon-P membranes (Millipore IH1079562, Billerica, MA, 
USA). Western blotting was performed with antisera specific for PDPN [18], GAPDH 
(Santa Cruz Biotechnology A1978, Santa Cruz, CA, USA), or β-actin (Sigma A1978, St. 
Louis, MO, USA), and recognized by appropriate secondary antiserum conjugated to 
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horseradish peroxidase and detected using enhanced chemiluminescence (Thermoscientific 
32106, Philadelphia, PA, USA) as described previously [5, 18, 25]. Membranes were stained 
with India ink to verify equal loading and transfer after blotting.
Kinase assays
A phosphocellulose paper binding assay was used to measure phosphorylation of the peptide 
VVMKKISGRFSP (>95% purity, synthesized by GenScript USA Inc., Piscataway, NJ, 
USA), containing the entire intracellular region of PDPN (residues 161–172) as described 
[18]. Reaction mixtures contained 700 µM peptide in 20 mM Tris-HCl (pH 7.5), 10 mM 
MgCl2, 1 mg/ml bovine serum albumin, 0.25 mM ATP, and [γ-32P]-ATP (100 cpm/pmol). 
Reactions were initiated by adding 80 µg/ml PKA (Promega V5161, Madison, WI, USA), 22 
µg/ml CDK5/p25 kinase enzyme (Promega V3231, Madison, WI, USA), or both PKA and 
CDK5/p25. Reactions were quenched after 10 minutes by the addition of 10% 
trichloroacetic acid, spotted onto P81 phosphocellulose filters, washed 3 times with 0.5% 
phosphoric acid, and analyzed by scintillation counting to determine picomoles of phosphate 
transferred. For mass spectrometry analysis, the kinase assay reactions contained 700 µM 
PDPN peptide in 30mM Tris-HCl (pH 7.5), 20 mM MgCl2, 1 mg/ml bovine serum albumin 
and 0.40 mM ATP.
Mass spectrometry
Peptide was purified (Millipore UFC501096 Carrigtwohill, Ireland) from kinase reactions 
and desalted (Millipore ZTC18M960, Billerica, MA, USA) according to manufacturer’s 
instructions. Peptide was then subjected to LC-MS/MS analysis on an Ultimate 3000 liquid 
chromatography (LC) system coupled with an Orbitrap Velos tandem mass spectrometry 
(MS/MS) instrument (Thermo Fisher Scientific, Philadelphia, PA, USA). Resulting MS/MS 
spectra were searched against a database containing PDPN peptide sequence using a local 
Mascot search engine (V.2.3). Methionine oxidation and serine/threonine phosphorylation 
were set as variable modifications in search parameters. Phosphopeptide sequence and 
phosphorylation sites were manually confirmed based on y- and b-ion series fragments.
Generation of mutant Pdpn cell lines
Pdpn single mutant constructs were produced with the QuikChange II XL Site-Directed 
Mutagenesis Kit according to the manufacturer’s protocol (Stratagene 200521, La Jolla, CA, 
USA). The vector pEF4Pdpn, encoding full length wild type mouse PDPN (PdpnWT) [18], 
was used as a template. PdpnSer167Ala, encoding PDPN with non-phosphorylatable serine 
at position 167 (PdpnS167A) was generated with the complementary primer pairs 
5’GTTGTTATGAAGAAGATTGCTGGAAGGTTCTCGCC3’, 
5’GGCGAGAACCTTCCAGCAATCTTCTTCATAACAAC3’ followed by 
5’GGTTCTCGCCCTAAAGAGGGCCCTTCGAAGG3’, 
5’CCTTCGAAGGGCCCTCTTTAGGGCGAGAACC3’. PdpnSer167Asp, encoding PDPN 




encoding PDPN with non-phosphorylatable serine at position 171 (PdpnS171A), was 
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generated with the complementary primers 
5’TGGAAGGTTCGCGCCCTAAAGAGGGCCCTTCGAAGG3’, 
5’CCTTCGAAGGGCCCTCTTTAGGGCGCGAACCTTCCA3’. PdpnSer171Asp, 
encoding PDPN with serine 171 mutated to phosphomimetic aspartate (PdpnS171D), was 
generated with the complementary primers 
5’TGGAAGGTTCGACCCCTAAAGAGGGCCCTTCGAAGG3’, 
5’CCTTCGAAGGGCCCTCTTTAGGGGTCGAACCTTCCA3’. All constructs were 
verified by sequencing. PdpnKo cells were stably transfected with PdpnS167A, PdpnS167D, 
PdpnS171A or PdpnS171D constructs and maintained in DMEM supplemented with 10% 
FBS as described [18]. Cells were cotransfected with PDPN constructs subcloned into 
pEF4Zeo, as well as pBabePuro, and selected for growth in both zeocin and puromycin, to 
achieve very high transfection efficiencies without taking clones as previously described [5, 
18, 32–34]. Clones were not taken to minimize potential effects of clonal variation, and 
experiments were done in parallel to control for differences in serum effects and other 
environmental factors between experiments.
Evaluation of cell migration
500,000 cells were seeded in each well of 12-well cluster plates (CytoOne CC7682-7512, 
Ocala, FL), allowed to form a monolayer, scratched at the center to create a wound, and 
migration was quantitated as the number of cells that entered a field of 400 × 400 micron in 
the center of the wound at 18 hours as previously described [5, 18, 25]. Data were taken 
from three representative experiments (n=3) with 5 fields per experiment. For some 
experiments, cells were treated with 20 µM PKA inhibitor H-89 (Calbiochem 371963) or 0.1 
µM CDK5 inhibitor Roscovitine (Calbiochem 557360) immediately after wounding.
Statistical analysis
Statistical analyses were performed using Prism (version 5, GraphPad Software).
Results
PKA and CDK5 phosphorylate the intracellular domain of PDPN
We generated cells from homozygous null PDPN knockout mice, called PdpnKo cells [18]. 
These cells serve as a clear foundation on which to examine the effects of specific PDPN 
isoforms and modifications on cell behavior. For example, as shown in Figure 1a, PDPN can 
be immunoprecipitated from these cells with phosphoserine antiserum, and then detected by 
Western blotting to demonstrate that it is phosphorylated by serine kinases in vivo.
The intracellular domain of PDPN contains 2 conserved serine residues. These serines are 
located at residues 167 and 171 in mouse PDPN, corresponding to serines 157 and 161 in 
human PDPN. We thus sought to identify which of these serines is phosphorylated to affect 
PDPN signaling events.
Kinase specific phosphorylation sites on PDPN intracellular domain were predicted using 
the ExPASy NetPhosK server. These analyses identified PKA and CDK5 as ideal candidates 
for kinases that phosphorylate the intracellular serines of PDPN. Therefore, a peptide 
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corresponding to the entire intracellular domain of PDPN was used as a substrate to evaluate 
the ability of PKA and CDK5 to phosphorylate these serine residues. As shown in Figure 1b, 
PKA transferred about 60 pmol of phosphates to the PDPN peptide in 10 minutes. These 
data are consistent with previous studies indicating that PKA can phosphorylate PDPN 
intracellular serines [18].
In addition to PKA, CDK5 also transferred about 40 pmol of phosphate to the PDPN peptide 
in 10 minutes (Figure 1b). Interestingly, simultaneous incubation with PKA and CDK5 
resulted in approximately 100 pmol of phosphate to the PDPN peptide in 10 minutes (Figure 
1b). Thus, PKA and CDK5 displayed an additive effect on PDPN phosphorylation. 
Although serine 167 of PDPN has been considered to be a putative PKC phosphorylation 
site [13], we did not detect PDPN peptide phosphorylation by PKC (data not shown).
PKA phosphorylates PDPN on S167 or S171, while CDK5 preferentially phosphorylates 
S171
We performed LC-MS/MS analysis of the PDPN peptide from in vitro kinase assays in 
order to determine which PDPN residues are phosphorylated by PKA and CDK5. As shown 
in Figure 2, treatment of the peptide with PKA or CDK5 resulted in singly phosphorylated 
species, in which either S167 or S171 was modified. MS spectra detected PDPN peptides 
with phosphorylation at serine 167 (S167) or serine 171 (S171) from PKA and CDK5 
treated samples. We did not detect any PDPN peptides with phosphorylation at both S167 
and S171 residues from these reactions (Figures 2 and 3). These data indicate that each 
kinase can phosphorylate one or the other serine in a single reaction, but not both.
The percent of PDPN peptide phosphorylated at S167 or S171 was calculated from spectra 
counts to determine if PKA and CDK5 preferentially phosphorylate specific serine residues. 
As shown in Figure 3, PKA phosphorylated PDPN on S167 or S171 equally well. However, 
CDK5 phosphorylated S171 four fold more than S167. These data indicate that PKA can 
phosphorylate PDPN equally well on either S167 or S171, whereas CDK5 preferentially 
phosphorylates PDPN on S171.
Both S167 and S171 residues on PDPN are phosphorylated to inhibit cell migration
We used homozygous null PDPN knockout mouse embryonic fibroblasts (PdpnKo cells) to 
evaluate how modification of each PDPN intracellular serine residue affects cell migration. 
As shown in Figure 4b, cells expressing wild-type PDPN (PdpnWT) migrated about 2 fold 
more than control PdpnKo cells transfected with empty parental vectors (PdpnEF4). 
Substitution of both intracellular serines to nonphosphorylatable alanines (PdpnAA cells) 
increased cell migration about 3 fold compared to PdpnWT cells. In contrast to cells 
expressing nonphosphorylatable PDPN, migration of cells expressing PDPN with both 
serines mutated to phosphomimetic aspartate (PdpnDD) was comparable to control 
transfectants. These data are consistent with previous studies indicating that phosphorylation 
of PDPN can decrease cell migration [18].
After examining double mutants, we generated cells expressing PDPN with single site 
mutations to examine the effects of phosphorylation of individual intracellular serine 
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residues on cell migration. PdpnKo cells were transfected with PDPN constructs with S167 
or S171 mutated to nonphosphorylatable alanine (PdpnS167A or PdpnS171A) and 
phosphomimetic constructs with these serines mutated to aspartate (PdpnS167D or 
PdpnS171D). After confirming PDPN expression by Western Blotting (Figure 4a), cell 
migration was evaluated by wound healing assays.
As shown in Figure 4b, cells expressing PDPN with either serine S167 or S171 mutated to 
alanine (PdpnS167A or Pdpn171A) migrated over twice as well as cells expressing wild 
type PDPN (PdpnWT). These data suggest that both of these serines need to be 
phosphorylated to effectively inhibit cell motility. As shown in Figure 4b, cells expressing 
any construct with a single serine of PDPN mutated to alanine or aspartate migrated 
comparably to cells expressing nonphosphorylatable PDPN - with both sites mutated to 
alanine (PdpnAA). As discussed below, these data indicate that both intracellular serines on 
PDPN are phosphorylated to decrease cell migration, and phosphomimetic residues can not 
fully compensate for these phosphorylation events.
Discussion
PDPN has emerged as a functionally relevant tumor biomarker and chemotherapeutic target 
[25, 35, 36]. Several ligands can bind to the extracellular region of PDPN to promote 
transformed cell migration and tumorigenesis [37–40]. Accordingly, this extracellular region 
can be targeted by reagents to inhibit tumor cell growth and motility [15, 25, 27, 28].
Regardless of extracellular signals, the intracellular region of PDPN must also direct events 
that affect cell migration. The two conserved serine residues in the short PDPN intracellular 
tail present a clear potential for biological relevance. Results from studies presented here 
indicate that phosphorylation of either serine in the PDPN tail is not sufficient to inhibit cell 
migration; they both need to be phosphorylated to inhibit cell motility.
Interestingly, PdpnWT cells treated with a PKA inhibitor migrated about 50% more than 
control cells, while CDK5 inhibition decreased cell migration by about 50% (Supplemental 
Figure 1). However, CDK5 regulates cell proliferation and morphology in addition to 
migration, and these pleiotropic effects may cause toxicities that prohibit cell motility in 
manners unrelated to PDPN signaling [41–43]. In addition, cells expressing phosphomimetic 
PDPN constructs with either intracellular serine mutated to aspartate (PdpnS167D or 
Pdpn171D) migrated twice as well as cells with wild type PDPN. Clearly, these 
phosphomimetic mutations do not reproduce PDPN modifications that result from 
phosphorylation events. These data are consistent with studies indicating that phosphate 
residues affect protein function in many ways, including alterations to potential adaptor 
binding sites and changes to the overall chemical environment that are not accomplished by 
changes of serines to aspartate or glutamate residues [44–46].
Taken together, these results suggest a scenario, outlined in Figure 6, in which PKA and 
CDK5 phosphorylate PDPN S167 or S171, respectively, in order to decrease cell motility. 
Previous studies found that PKA can phosphorylate PDPN on one or both intracellular 
serines to decrease cell migration [18]. Here, we show that both serines need to be 
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phosphorylated in order to decrease cell migration. Moreover, these data indicate that PKA 
can phosphorylate PDPN on either serine, while CDK5 appears to phosphorylate S171. 
Therefore, a coordinated effort by unrelated kinases is required to phosphorylate PDPN in 
order to inhibit cell motility.
Identification of PKA and CDK5 as kinases that phosphorylate specific residues on PDPN to 
affect cell migration should help elucidate mechanisms that control processes including 
embryonic development, tumorigenesis, and chemotherapeutic treatments. For example, 
chemotherapeutic agents such as disulfiram and CARP-1 functional mimetics have recently 
been found to induce PDPN phosphorylation. Moreover, PDPN phosphorylation induced by 
these anticancer reagents leads to PDPN degradation and mesothelioma cell growth 
inhibition [31, 47]. Further elucidation of how PDPN phosphorylation controls cell growth 
and motility should yield fundamental insights into many important biological and 
biomedical processes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• We examined the dynamics of PDPN phosphorylation and its role in cell 
migration.
• PKA and CDK5 phosphorylate the intracellular domain of PDPN.
• PKA can phosphorylate PDPN on S167 or S171.
• CDK5 preferentially phosphorylates PDPN on S171.
• Both S167 and S171 residues on PDPN are phosphorylated to inhibit cell 
motility.
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Figure 1. PKA and CDK5 phosphorylate serine residues in the PDPN intracellular domain
(a) Total protein (input) and protein immunoprecipitated with phosphoserine antiserum (pS 
IP) from homozygous null PdpnKo cells transfected with empty parental vector (EF4) or 
wild type PDPN (WT) was analyzed for PDPN and GAPDH by Western blotting as 
indicated. (b) Peptide containing the entire intracellular region (VVMKKISGRFSP) of 
PDPN was incubated with PKA, CDK5, or both PKA and CDK5 along with [γ-32]ATP for 
10 minutes. Data are shown as picomoles of phosphate incorporated into the PDPN peptide 
(mean+SD, n=2). Asterisks indicate p<0.05 compared to CDK5 treated cells by t-Test.
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Figure 2. PKA and CDK5 phosphorylate either PDPN S167 or S171
Peptide containing the entire intracellular region (VVMKKISGRFSP) of PDPN was 
incubated with PKA, CDK5, or both PKA and CDK5 along with [γ-32]ATP for 10 minutes. 
Representative MS/MS spectrum of PKA and CDK5 treated samples show doubly-charged 
ion (m/z 714.87) corresponding to the phosphorylated PDPN peptide sequence with 
phosphorylation at S167 or S171 as indicated. Observed y-ion and b-ion series confirming 
the peptide sequence and phosphorylation sites are also shown.
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Figure 3. PKA phosphorylates S167 or S171, while CDK5 preferentially phosphorylates S171 in 
the PDPN intracellular domain
Peptide containing the entire PDPN intracellular region was treated with PKA or CDK5 as 
indicated, and analyzed by LC-MS/MS to detect specific phosphorylation sites. Data are 
shown as the percent of PDPN peptide phosphorylated at serine residues position 167 or 171 
based on at least 100 MS spectra counts.
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Figure 4. Both serine residues in the intracellular domain of PDPN are phosphorylated to 
decrease cell migration
(a) PDPN and β-actin were detected by Western Blotting of protein (10 µg/lane) from 
homozygous null Pdpn knock-out mouse embryonic fibroblasts transfected with empty 
parental vectors (EF4), wild type Pdpn (WT), Pdpn with both intracellular serines mutated to 
alanine (AA), Pdpn with both intracellular serines mutated to aspartate (DD), or Pdpn with 
each of the 2 serines mutated to alanine or aspartate (S167A, S167D, S171A, S171D) as 
indicated. (b) Cell migration was measured by wound healing assays, and quantitated as the 
number of cells that entered 400 × 400 µm field in the center of a wound within 18 hours 
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(mean+SEM, n=3). Single, double, and triple asterisks indicate p<0.05, 0.01, or 0.001 by t-
Test compared to EF4 cells, respectively.
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Figure 5. Phosphorylation of specific serines on the PDPN intracellular domain affect cell 
migration
PKA can phosphorylate serines S167 or S171 on the intracellular domain of PDPN, whereas 
CDK5 preferentially phosphorylates S171. However, phosphorylation of both intracellular 
serines on PDPN is required to inhibit PDPN mediated cell migration. Thus, PKA and 
CDK5 may phosphorylate PDPN S167 and S171, respectively, in order to decrease cell 
motility.
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